Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the disease activity score in patients with early rheumatoid arthritis

Journal of Rheumatology

Volumn 26, Issue 11, 1999, Pages 2324-2331

  Paulus, Harold E ^a   Ramos, Brian ^b   Wong, Weng Kee ^b   Ahmed, Alaa ^b   Bulpitt, Ken ^b   Park, Grace ^b   Sterz, Mildred ^b   Clements, Philip ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

ACR 20 improvement criteria; C reactive protein; Disease activity score; Erythrocyte sedimentation rate; Plasma viscosity; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ACUTE PHASE RESPONSE; ADULT; ARTHRITIS; ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PLASMA VISCOSITY; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0032752807     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
2. Food and Drug Administration. Guidance for industry: clinical development programs for drugs, devices and biological products for the treatment of rheumatoid arthritis [draft]. Washington: US Food and Drug Administration, March 1998.
3. Food and Drug Administration. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products [draft]. Washington: US Food and Drug Administration, March 13, 1997.
4. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-85.
5. Ahmed AA. Acute phase proteins. In: Peter JB, Reyes HR, editors. Use and interpretation of tests in rheumatology. Santa Monica: Specialty Medical Laboratories; 1996:237-56.
6. Gudmundsson M, Bjelle A. Plasma viscosity in the monitoring of therapy in rheumatoid arthritis patients. Scand J Rheumatol 1995;24:219-24.
7. Kirwan JR and the Arthritis and Rheumatism Council Low-dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
8. Harkness J. The viscosity of human blood plasma: its measurement in health and disease. Biorheology 1971;8:171-93.
9. Crockson RA, Crockson AP. Relationship of the erythrocyte sedimentation rate to viscosity and plasma proteins in rheumatoid arthritis. Ann Rheum Dis 1974;33:53-6.
10. Dixon JS. Relationship between plasma viscosity or ESR and Ritchie articular index. Br J Rheumatol 1984;3:233-5.
11. Bull BS, Westengard JC, Farr M, Bacon PA, Meyer PJ, Stuart J. Efficacy of tests used to monitor rheumatoid arthritis. Lancet 1989;2:965-7.
12. Dinant GJ, Habets GPA, van der Tempel H, Knottnerus JA. Discriminating ability of plasma viscosity and erythrocyte sedimentation rate: a prospective study at the rheumatology out-patient department. Scand J Rheumatol 1992;21:186-9.
13. Bradley SM, Le Gallez P, Throughton PR, Gooi HC, Astbury C, Bird HA. The effect of sulphasalazine on neutrophil superoxide generation in rheumatoid arthritis. Br J Rheumatol 1997;36:530-4.
14. Hewlett SE, Haynes J, Shepstone L, Kirwan JR. Rheumatoid arthritis patients cannot accurately report signs of inflammatory activity. Br J Rheumatol 1995;34:547-53.
15. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995;13:17-22.
16. Astbury C, Platt R, Dixon JS, Le Gallez P, Hill J, Bird HA. Optimizing the assessment of disease activity during treatment with anti-rheumatoid drugs. Br J Rheumatol 1993;32:467-73.
17. Van der Heijde DMFM, van't Hof MA, van Riel PLCM, van Leeuwen MA, van Rijswijk MH, van de Putte LBA. A comparison of validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
18. Van der Heijde DMFM, van't Hof MA, van Riel PLCM, et al. Judging disease activity in clinical practice in rheumatoid arthritis; first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
19. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
20. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. QJ Med 1968;37:393-406.
21. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
22. Fisher LD, Belle VG. Biostatistics: a methodology for the health sciences. New York: John Wiley; 1993.
23. Boroviczeny KG, Dintenfass L, Fukada E, et al. Recommendation for a selected method for the measurement of plasma viscosity. J Clin Pathol 1984;37:1147-52.
24. Kanakoudi F, Drossou V, Tzimouli V, et al. Serum concentrations of 10 acute phase proteins in healthy term and pre-term infants from birth to age 6 months. Clin Chem 1995;41:605-8.